Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
Recruiting
N/A
Interventional Study
Diabetes
IPMN, Pancreatic
PDAC - Pancreatic Ductal Adenocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 400 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real e…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
\*\*Inclusion criteria for patients with PDAC and IPMN:\*\*
* No history of prior neoplastic diseases;
* Adequate renal and hepatic function;
* No hematologic disorders;
* Age ≥ 18 years;
* No active infections;
* Written informed consent.
\*\*Exclusion criteria:\*\*
* Severe pre-existing medical…
Contacts